Coronary Stent Restenosis in Patients Treated With Cilostazol

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Circulation

• Publication date

  2005-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.104.530097PMID 16246948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial

  2004cited by this paper
• Folate therapy and in-stent restenosis after coronary stenting.

  2004cited by this paper
• Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

  2004influential reference
• Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents

  2004cited by this paper
• Economic impact of drug-eluting stents on hospital systems: a disease-state model.

  2004influential reference
• A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

  2004cited by this paper
• Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious?

  2004cited by this paper
• A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.

  2004influential reference
• Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.

  2004influential reference
• Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

  2003cited by this paper
• Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.

  2003cited by this paper
• Rationale and design of the randomized, multicenter, Cilostazol for restenosis (CREST) trial

  2003influential reference
• Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial

  2002cited by this paper
• Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.

  2002influential reference
• Systemic drug therapy for restenosis: "déjà vu all over again".

  2002cited by this paper
• Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.

  1999cited by this paper
• Comparison of cilostazol versus ticlopidine therapy after stent implantation.

  1999cited by this paper
• Predictive factors of restenosis after coronary stent placement.

  1997influential reference
• A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation.

  1997influential reference
• Pharmacologic Treatment of Intimal Hyperplasia After Metallic Stent Placement in the Peripheral Arteries: An Experimental Study

  1995cited by this paper
• A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

  1994cited by this paper
• A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

  1994cited by this paper
• Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.

  1994cited by this paper
• A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease

  1994cited by this paper

• Effectiveness of Cilostazol Treatment in Femoropopliteal Artery Disease After Drug-Coated Balloon Therapy: Subanalysis of the POPCORN Study.

  2025cites this paper
• Effect of triple versus dual antiplatelet therapy in patients undergoing percutaneous intervention: systematic review and meta-analysis with GRADE system

  2025cites this paper
• An increase in flow-diverter oversizing values as an independent risk factor for developing more severe in-stent stenosis. A retrospective single-center study based on flow diversion of supraclinoid internal carotid artery aneurysms

  2025cites this paper
• Innovations in Vascular Repair from Mechanical Intervention to Regenerative Therapies

  2025cites this paper
• Outcomes of Carotid Artery Stenting and Endarterectomy in Patients with Prior Contralateral Carotid Revascularization.

  2024cites this paper
• The NITRATE-OCT study-inorganic nitrate reduces in-stent restenosis in patients with stable coronary artery disease: a double-blind, randomised controlled trial

  2024cites this paper
• The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis

  2024cites this paper
• Randomized Controlled Trial of Cilostazol Addition for In-Stent Restenosis After Carotid Artery Stenting

  2024cites this paper
• Phosphodiesterase in heart and vessels: from physiology to diseases

  2023cites this paper
• Clinical Impact of Additional Cilostazol Treatment on Restenosis Risk following Heparin-Bonded Stent Graft Implantation: Sub-Analysis from the Viabahn Stent-Graft Placement for Femoropopliteal Diseases Requiring Endovascular Therapy (VANQUISH) Study

  2023cites this paper
• The contemporary use of intracoronary brachytherapy for instent restenosis: A review.

  2023cites this paper
• Genetic Variants in PHACTR1 & LPL Mediate Restenosis Risk in Coronary Artery Patients

  2023cites this paper
• Dipyridamole and vascular healing following stent implantation

  2023cites this paper
• Efficacy and Safety of Cilostazol-Based Triple Antiplatelet Therapy Compared with Clopidogrel-Based Dual Antiplatelet Therapy in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Multicenter, Randomized, Open-Label, Phase 4 Trial.

  2023cites this paper
• Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease

  2023cites this paper
• A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease

  2022cites this paper
• Cardiovascular Protection Associated With Cilostazol, Colchicine, and Target of Rapamycin Inhibitors

  2022cites this paper
• The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis

  2022cites this paper
• Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors

  2022cites this paper
• Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation

  2022cites this paper
• Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long‐term follow‐up of the ESCAPE study

  2022cites this paper
• Gradual Expansion of a Stent to Prevent Periprocedural Complications after Carotid Artery Stenting for Vulnerable Severe Stenotic Lesions with Intraplaque Hemorrhages: A Retrospective Observational Study

  2022cites this paper
• Cilostazol for Secondary Stroke Prevention

  2021cites this paper
• Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications

  2021cites this paper
• An overview of in-stent restenosis in iliofemoral venous stents.

  2021cites this paper
• Revisiting the evidence for dipyridamole in reducing restenosis: a systematic review and meta-analysis.

  2021cites this paper
• Treatment of In-Stent Stenosis Following Flow Diversion of Intracranial Aneurysms with Cilostazol and Clopidogrel

  2021cites this paper
• Molecularly imprinted polymer nanoparticles-based electrochemical chemosensors for selective determination of cilostazol and its pharmacologically active primary metabolite in human plasma.

  2021cites this paper
• Cilostazol: a Review of Basic Mechanisms and Clinical Uses

  2021cites this paper
• [Prospects of clinical application of cilostazol for peripheral artery disease].

  2020cites this paper
• Perioperative Management of Antiplatelet Therapy in Ophthalmic Surgery

  2020cites this paper
• Novel antiplatelet targets in the treatment of acute coronary syndromes

  2020cites this paper
• Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk

  2020cites this paper
• Cilostazol Decreases Endothelin-1 Level in Patients with an Acute Coronary Syndrome: A Prospective Study

  2020cites this paper
• Efficacy and Safety of Dual-Drug-Eluting Stents for de Novo Coronary Lesions in South Korea—The Effect Trial

  2020cites this paper
• Therapeutic potential of phosphodiesterase inhibitors for endothelial dysfunction-related diseases.

  2020cites this paper
• Effect of cilostazol, a phosphodiesterase‐3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study

  2019cites this paper
• The contemporary hybrid operative procedure for incapacitating post-thrombotic iliofemoral and vena caval obstruction improves procedural outcomes.

  2019cites this paper
• Sildenafil Reduces Neointimal Hyperplasia after Angioplasty and Inhibits Platelet Aggregation via Activation of cGMP-dependent Protein Kinase

  2019cites this paper
• Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.

  2019cites this paper
• Outcomes with cilostazol after endovascular therapy of peripheral artery disease

  2019cites this paper
• Phosphodiesterase Inhibitors

  2019cites this paper
• Role of and Recent Evidence for Antiplatelet Therapy in Prevention of Cardiovascular Disease in Diabetes

  2019cites this paper
• Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits

  2018cites this paper
• Novel short isoforms of adenylyl cyclase as negative regulators of cAMP production.

  2018cites this paper
• MicroRNA-132 targeting PTEN contributes to cilostazol-promoted vascular smooth muscle cell differentiation.

  2018cites this paper
• Medical Treatment of Intracranial Atherosclerosis: An Update

  2017cites this paper
• Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis

  2017cites this paper
• Endarterectomy versus stenting in patients with prior ipsilateral carotid artery stenting

  2017cites this paper
• Drug‐eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease

  2017cites this paper
• Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.

  2017cites this paper
• The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis

  2017cites this paper
• Maintenance of Hemodialysis Vascular Access and Prevention of Access Dysfunction: A Review.

  2017cites this paper
• Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial.

  2017cites this paper
• Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.

  2017cites this paper
• Efficacy of CilostAzol for Below-the-Knee Artery Disease after Balloon AnGioplasty in PatiEnts with Severe Limb Ischemia (CABBAGE Trial).

  2017cites this paper
• The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial.

  2017cites this paper
• Cilostazol May Improve Maturation Rates and Durability of Vascular Access for Hemodialysis

  2017cites this paper
• GT-repeat length polymorphism in heme oxygenase-1 promoter determines the effect of cilostazol on vascular smooth muscle cells.

  2016cites this paper
• Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent Placement

  2016cites this paper
• Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention

  2016cites this paper
• Prevention of Femoropopliteal In-Stent Restenosis With Cilostazol

  2016cites this paper
• The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.

  2016cites this paper
• Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-&ggr; and cAMP Pathways in Vascular Cells

  2016cites this paper
• Antithrombotic Therapy.

  2016cites this paper
• Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.

  2016cites this paper
• Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: A meta-analysis of randomized controlled trials.

  2015cites this paper
• Risks and Benefits of Triple Oral Anti-Thrombotic Therapies After Acute Coronary Syndromes and Percutaneous Coronary Intervention

  2015cites this paper
• Role of Oral Therapies in the Prevention of Coronary Restenosis: Insights from Randomized Clinical Trials

  2015cites this paper
• The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases

  2015cites this paper
• Management Strategies for Clopidogrel Hypersensitivity

  2015cites this paper
• Cilostazol does not improve peripheral arterial disease-linked oxidative stress.

  2015cites this paper
• Continuous daily use of cilostazol prevents in-stent restenosis following carotid artery stenting: serial angiographic investigation of 229 lesions

  2015cites this paper
• Anti-inflammatory therapies for atherosclerosis

  2015cites this paper
• articleTriple antiplatelet therapy for preventing vascular events : a systematic review and meta-analysis

  2015cites this paper
• An unusual case of acute respiratory failure in a patient with pulmonary veins stenosis late after catheter ablation of atrial fibrillation: a case report and the review of the literature

  2015cites this paper
• Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature

  2015cites this paper
• Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model

  2015cites this paper
• Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials

  2015cites this paper
• Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease

  2015cites this paper
• New therapeutic effects of cilostazol in patients with ischemic disorders.

  2015cites this paper
• Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy

  2014cites this paper
• The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects.

  2014cites this paper
• Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials

  2014cites this paper
• Advances in targeting cyclic nucleotide phosphodiesterases

  2014cites this paper
• Population Pharmacokinetic Analysis of Diurnal and Seasonal Variations of Plasma Concentrations of Cilostazol in Healthy Volunteers

  2014cites this paper
• Effect of Pioglitazone on In-Stent Restenosis after Coronary Drug-Eluting Stent Implantation: A Meta-Analysis of Randomized Controlled Trials

  2014cites this paper
• Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents

  2014cites this paper
• Intelligent telemetric stent for wireless monitoring of intravascular pressure and its in vivo testing

  2014cites this paper
• Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.

  2014cites this paper
• Cilostazol and freedom from amputation after lower extremity revascularization.

  2014cites this paper
• Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons

  2014cites this paper
• Cilostazol Decreases Cerebral Arterial Pulsatility in Patients with Mild White Matter Hyperintensities: Subgroup Analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) Study

  2014cites this paper
• Effects of cilostazol on arterial wound healing: a retrospective analysis.

  2014cites this paper
• Intelligent telemetric stent for wireless monitoring of intravascular pressure and its in vivo testing

  2014cites this paper
• Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials

  2014cites this paper
• Pharmacological inhibition of coronary restenosis: systemic and local approaches

  2014cites this paper
• Cilostazol: an antiplatelet agent for the neurointerventionist?

  2014cites this paper
• Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol.

  2014cites this paper
• Antiagregación oral en el intervencionismo coronario percutáneo: fármacos disponibles y duración de la terapia oral

  2013cites this paper